Fatal Heart Disease Has Plummeted Since 1990, But Progress Has Stalled

Translate to Spanish or other 102 languages!

After decades of decline, fatal coronary heart disease may rise again unless Americans modify three major risk factors: smoking, drinking, and obesity. Image for illustration purposes
After decades of decline, fatal coronary heart disease may rise again unless Americans modify three major risk factors: smoking, drinking, and obesity. Image for illustration purposes

Mega Doctor News

- Advertisement -

By Rutgers University-New Brunswick

Newswise — After decades of decline, fatal coronary heart disease may rise again unless Americans modify three major risk factors: smoking, drinking, and obesity.

A Rutgers study just published in American Heart Journal found that deaths from coronary heart disease among people ages 25 to 84 dropped to 236,953 in 2019 from 397,623 in 1990, even though Americans’ median age increased to 38 from 33 over the last three decades.

- Advertisement -

Between 1990 and 2019, the US age-standardized coronary heart disease mortality rate per 100,000 fell from 210.5 to 66.8 for females (4 percent decline per year) and from 442.4 to 156.7 for males (3.7 percent decline per year). However, the decline has slowed significantly since 2011. Those born after 1980 were actually at slightly increased risk of dying from coronary heart disease at any age than people from the previous generation.

The findings echo those from the same team’s investigation of stroke-related deaths in the US.

Rutgers researchers noted while future advances in treatment continue reducing fatal heart disease, complementary lifestyle modifications may play an important role. It estimated that the elimination of smoking, drinking, and obesity would have prevented half of the deaths observed during the study period.

“The overall numbers are good. We saw a substantial decline in deaths from all types of coronary heart disease for both females and males,” said Cande Ananth, chief of the Division of Epidemiology and Biostatistics in the Department of Obstetrics, Gynecology, and Reproductive Sciences at Rutgers Robert Wood Johnson Medical School, and lead author of the study. “However, because we examined how these three modifiable risk factors affected mortality rates, we can see that there is room for considerable improvement.”

- Advertisement -

Tobacco usage is already headed in the right direction: The percentage of Americans who smoked tobacco fell to 14 percent in 2019 from 26 percent in 1990. Obesity rates, on the other hand, rose sharply during the study period to 43 percent in 2019 from 12 percent in 1990. Alcohol usage rose slightly during the study period. 

In addition to the reduction in smoking, other factors driving the decline in coronary heart disease mortality included statins (which lower cholesterol), better diagnostic tests, and more frequent use of those tests.

“Although myocardial infarctions happen without warning, the other two major types of coronary heart disease — chronic ischemic heart disease and atherosclerotic heart disease — can be diagnosed and treated years before they damage the heart muscles,” said Ananth, whose analyses of past trends aspire to improve future care.

To achieve this, Ananth’s research team analyzes the largest possible datasets to differentiate risk among various patient subsets. The new study used anonymized data from the National Center for Health Statistics to track all heart disease fatalities in the targeted age range for the three-decade period.

“The ultimate goal is to help inform standards of care and public health priorities by determining which patients face the highest level of risk for cardiovascular events,” Ananth said. “Although increased screening and population-wide interventions are possible, the returns are likely to be minimal, at best, while costs will be prohibitively high. We need to maximize returns from our limited resources by identifying high-risk subsets of patients and targeting intervention to them.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Launches Expedited IND Pilot to Speed Up Clinical Trials

The U.S. Food and Drug Administration today announced the final design of the Expedited Investigational New Drug (IND) Pilot. Accelerating clinical trial timelines and eliminating regulatory hurdles to maintain American leadership in global medical innovation is a core priority for the Trump Administration.

Navigating Cardiovascular Health in Hispanic Communities

Cardiovascular disease is the leading cause of death for Hispanic and Latino people in the United States. But the challenges they face are hardly the whole story, say experts who helped write a new report on the heart health of these communities.

Easy Ways to Turn Picky Eaters Into Happy Eaters

September is National Fruits and Veggies Month. If you have a little one who isn’t a big fan of either, you’re in good company. It’s common for kids to be picky eaters.

New AI Tool Accurately Predicts Lung Cancer Immunotherapy Results

Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine.
- Advertisement -